Jump to content

ORG-24598

From Wikipedia, the free encyclopedia
ORG-24598
Names
IUPAC name
2-[Methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
  • InChI=1S/C19H20F3NO3/c1-23(13-18(24)25)12-11-17(14-5-3-2-4-6-14)26-16-9-7-15(8-10-16)19(20,21)22/h2-10,17H,11-13H2,1H3,(H,24,25)/t17-/m1/s1
    Key: KZWQAWBTWNPFPW-QGZVFWFLSA-N
  • CN(CCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F)CC(=O)O
Properties
C19H20F3NO3
Molar mass 367.368 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

ORG-24598 is a selective inhibitor of the type 1 glycine transporter.[1]

Potential uses

[edit]

Alcohol use disorder

[edit]

A test in rats has showed that combining varenicline, bupropion, and an indirect glycine agonist (such as ORG-24598) could be beneficial for treatment of alcohol use disorder.[2]

Schizophrenia

[edit]

Studies have shown that glycine re-uptake inhibitors selective for the type 1 transporter may be useful for the treatment of certain schizophrenia symptoms.[3][4]

References

[edit]
  1. ^ "2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-17.
  2. ^ Olsson, Yasmin; Lidö, Helga; Ademar, Karin; Cadeddu, Davide; Ericson, Mia; Söderpalm, Bo (January 2024). "The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats". Journal of Neural Transmission (Vienna, Austria: 1996). 131 (1): 95–106. doi:10.1007/s00702-023-02701-x. ISSN 1435-1463. PMC 10769923. PMID 37773223.
  3. ^ Chue, Pierre (2013). "Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)". Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN 1873-4286. PMID 23194655.
  4. ^ Javitt, Daniel C. (July 2002). "Glycine modulators in schizophrenia". Current Opinion in Investigational Drugs (London, England: 2000). 3 (7): 1067–1072. ISSN 1472-4472. PMID 12186269.